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Abstract
Background: In the literature, data on the prevalence of human papillomavirus (HPV) infection in men vary
significantly and the exact distribution of specific genotypes is still unclear. As infections usually occur without
symptoms, men might only attend their hospital clinic when they have a specific concern, being in most cases
genital warts (condylomas), which are often caused by low-risk HPV genotypes. The aim of this study was to assess
HPV genotype distribution and prevalence among men attending hospital for HPV-associated conditions and to
evaluate infection-associated factors.
Methods: Samples from men with clinical manifestations of HPV-related infections seen during 2007–2012 at the
Clinical Microbiology and Infectious Control Department at Basurto University Hospital were genotyped using
Linear Array HPV Genotyping Test kit (Roche Molecular Diagnostics, Germany). Data on probable risk factors were
collected and investigated for possible association.
Results: Of 184 anogenital samples, 138 (75 %) were tested as positive for HPV; 57 (41.3 %) single HPV infections
and 81 (58.7 %) multiple infections. Only 45.6 % of HPV-positive samples presented low-risk genotypes 6 or 11,
whereas 71/138 (51.4 %) had at least one oncogenic (high-risk) genotype. Oncogenic genotypes and multiple HPV
infections were both associated with a higher number of lifetime sexual partners and their incidence appeared to
increase with patient age.
Conclusions: Although it is accepted that HPV 6 and 11 genotypes are main causes of condylomas, our findings
show a high incidence of multiple infections and high-risk genotypes in men with benign HPV manifestations. The
fact that the condyloma is a skin lesion facilitates the entry of virus into cells and thus cancer progression; therefore,
monitoring for HPV is important, especially in those patients with high-risk genotypes (regardless of whether they
cause condyloma).
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Background
At present, human papillomavirus (HPV) infections are
the most commonly diagnosed sexually transmitted dis-
ease [1]. Most infections are asymptomatic and disappear
without treatment within a few months [2]. However,
some HPV infections can persist for many years causing
cell abnormalities, which, if untreated, have the potential
to develop into cancer [3].
As infections are sexually transmitted, both men and
women can be carriers of HPV. Infections in men usu-
ally occur without symptoms, but, unlike women, there
are no recommended or approved screening programs
for asymptomatic infections in men [4–6]. Furthermore,
men often only go to the hospital clinic in the event of a
specific concern, being in most cases, a genital wart
(condyloma acuminatum).
Ninety percent of condyloma acuminata are caused by
two low oncogenic risk genotypes, HPV 6 and 11 [1, 7, 8].
However, as multiple HPV infections with more than one
HPV genotype are common and patients are usually
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Arroyo et al. BMC Public Health  (2016) 16:81 Page 2 of 8sexually active, additional genotypes might also be present
on genital warts, including genotypes that are associated
with a higher oncogenic risk, such as HPV 16. This geno-
type has been reported as the third most common geno-
type detected in condylomas after HPV 6 and HPV 11 in
genital warts [7, 9].
In the literature, data on HPV infection prevalence in
men vary significantly (1.3 % to 72.9 %) and the exact
distribution of specific HPV genotypes remains unclear
[10, 11]. Condyloma skin lesions, although benign, facili-
tate the entry of HPV into cells, and thus increase the
risk of cancer development [12]. Therefore, monitoring
for the presence of various HPV genotypes might be
important, especially in those patients with known high-
risk HPV types.
The aim of this study was to assess HPV genotype dis-
tribution among men with benign clinical manifestations
of HPV-related infections and to evaluate factors associ-
ated with HPV infection.
Methods
Ethics statement
This study was performed with the approval of Clinical
Research Ethics Committee at Basurto University Hospital
(Bilbao, Bizkaia, Spain) and all procedures were in accord-
ance with the guidelines and ethical standards for experi-
mental investigation with human subjects required by the
Helsinki Declaration of 1975, as revised in 2000.
All patients gave written and informed consent prior
their inclusion in the study and parents provided written
informed consent on behalf of children (<18 years old)
enrolled in our study.
Recruitment of participants
All men attending the Consultation of Sexually Transmit-
ted Diseases (CSTD) clinic at Basurto University Hospital
from 2007 to 2012 due to a lesion in the genital area that
urologists suspected as being potentially caused by HPV
were eligible for recruitment to the study. No selected
groups were used.
Sample collection
Lesions were tape-stripped to remove possible environ-
mental contaminations [13] and samples were collected
by urologists with a saline-wetted Dacron swab device
[14]. This device was chosen for sampling due to its
greater efficiency compared with cytobrush devices [14].
Sample adequacy was evaluated by amplification of the
ß-globin gene with real-time polymerase chain reaction
(PCR) [14] and only β-globin positive specimens were
included in the study. Samples were stored in their own
standard transport medium at -80 °C until they were
analysed for HPV presence. The validity of this methodfor the detection of HPV has been shown previously
[14, 15].
Data on medical diagnosis, age at diagnosis, location
of lesion, sexual behaviour (type of sexuality) and num-
ber of lifetime sexual partners were part of the medical
history collected from each individual during the med-
ical consultation at the time of sample collection.HPV DNA detection and genotyping
DNA was isolated and molecular genotyping was carried
out using a Linear Array HPV Genotyping Test kit
(Roche Molecular Diagnostics, Germany), according to
manufacturer’s instructions. HPV genotyping was per-
formed by amplifying a fragment of the L1 gene.
This genotyping kit is capable of identifying up to 37 ge-
notypes. HPV genotypes 16, 18, 31, 33, 35, 39, 45, 51, 52,
56, 58, 59, 68, 73 and 82 were considered to be high-risk
types, whereas HPV 26, 53 and HPV 66 were defined as
probable high-risk types [16]. All other HPV genotypes
were classified as low-risk types.
Men were considered to have a high-risk HPV infection
if they were positive for one or more high-risk HPV geno-
types – whether or not they were also positive for one or
more low-risk HPV genotypes. On the other hand, men
were considered to have a low-risk HPV infection if they
were positive only to low-risk HPV genotypes.
Genotyping was repeated twice (three times in total)
to confirm the result when a multiple genotype HPV in-
fection was detected or a negative result was obtained.
Negative and positive controls were provided with the
kit and used in every test.Statistical analysis
The association between the different variables was de-
termined using the chi-square test. Fisher’s exact test
was also performed when the expected numbers were
small as it is more accurate than the chi-square test in
this situation. SPSS 11.0.1 software (SPSS, Inc. Chicago,
IL) was used for the data analysis and a p-value below
0.05 was considered to be statistically significant.
Principal Component Analysis (PCA) was performed
to compare the genotypes of the HPV infections based
on the age, number of lifetime sexual partners and sex-
ual behaviour of the men, In order to do this, men were
classified into three age groups (below 30 years, 31–40
years and over 40 years old) and stratified into one of
five number of sexual partners groups (<2, 2–5, 6–10
or >10 lifetime sexual partners). Regarding sexual be-
haviour, a man was categorised as MSM (Men that had
Sex with Men) if the participant reported having had
sex (anal or oral sex) with another man in his lifetime.
All of these PCA analyses were performed using the
Unscrambler® software (CAMO).
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A total of 184 β-globin positive anogenital samples were
obtained for the study (1 sample per patient) and all
specimens were classified by urologists as cauliflower-
like growths. No flat lesions or stem-like protrusions
were detected.
One hundred and thirty eight specimens (75.0 %)
tested positive for HPV (Table 1), including 57 (41.3 %)
specimens with a single HPV infection and 81 (58.7 %)
specimens with multiple HPV genotype infections. The
remaining 46 samples were HPV negative but positive
for β-globin.
Low-risk genotypes HPV 6 and/or HPV 11 were de-
tected in 63/138 (45.6 %) of the positive samples. Sixty
two of these (44.9 %) showed the presence of only low-
risk HPV genotypes and single infections were detected
in 45 of these cases (68.1 %). The main HPV genotypes
detected in these low-risk infection specimens were:
HPV 6 (32/62), 11 (11/62) and 62 (7/62). In contrast, 71
samples (51.4 % of HPV-positive samples) showed the
presence of at least one oncogenic (high-risk) HPV
genotype, and multiple HPV infection was detected in
60 (84.5 %) of these cases. High-risk HPV predominant
types in these samples were: HPV 16 (30/71), 52 (22/71),
and 33 (8/71). In this group, the predominant low-risk
genotypes associated with high-risk multiple infections
were HPVs 6 and 84. The combination of HPV 6 or 11
plus at least one high-risk genotype was detected in 24
specimens.
Comparing the HPV genotypes detected in each type
of infection (single vs. multiple infection), a significant
difference was found (p < 0.0001). High-risk genotypes
were more frequently found in multiple infections, whileTable 1 Human papillomavirus (HPV) genotypes detected in 138 HP
Location Samples MSM Heterosexual SI
Penile area
Foreskin 12 3 9 6
Glans 12 3 9 5
Meatus 12 3 9 3
Shaft 53 22 31 27
Anal area
Perineum 19 9 10 5
Anus 29 13 16 11
Scrotum 1 1 0 0
Total 138 54 84 57
Statisticsa
Chi–square 1.591 1.591 2.081
p-value 0.21 0.21 0.15
HPV 6,11 infections where HPV6 and/or HPV11 were detected, HR high-risk genotyp
with other men, OHR only high-risk genotypes, OLR only low-risk genotypes, SI sing
aStatistical association between variables and location of warts considered both pen
consideration due to small sample sizelow-risk types were more commonly detected in single
infections (Fig. 1). However, 19 samples were positive for
only high-risk types and 11 of these (57.9 %) were single
infections.
Location of the lesions
The location of the genital warts are shown in Table 1.
The presence of single infection, multiple infection, HPV
6 and/or HPV 11, low-risk infection, high-risk infection,
and sexual behaviour were all studied for a possible associ-
ation with wart location. However, scrotum location was
not added to the analysis due to small sample size (n = 1).
Overall, multiple infections showed predominance in
both the penile area (48 multiple infections vs. 41 single
infections) and the anal area (32 multiple infections vs.
16 single infections) and the proportion of multiple in-
fections seemed to be higher in anal location. However,
these results were not statistically significant and could
not be used to establish an association between the type
of infection and condyloma location.
Men in the MSM group had a higher proportion of anal
condylomas than heterosexuals but again statistical ana-
lysis did not reveal a significant association. The rest of
variables that were analysed did not show any correlation
with the location of genital (p > 0.1; Table 1).
Age of the patient
The age of patients ranged from 17 to 72 years. The
prevalence of multiple HPV infections tended to in-
crease with age (49 % [25/51] in men aged <30 years,
63.6 % [28/44] in men aged 31–40 years, and 65.1 %
[28/43] in men aged >40 years). Similarly, the proportion
of patients with at least one high-risk genotype alsoV-positive genital samples
MI HPV 6,11 LR HR OLR OHR
6 5 11 6 6 1
7 0 7 8 4 3
9 2 6 8 2 6
26 28 45 25 26 5
14 11 15 11 8 3
18 16 28 13 15 1
1 1 1 0 1 0
81 63 113 71 62 19
2.081 3.605 3.038 0.099 0.344 1895
0.15 0.06 0.08 0.75 0.56 0.17
es, LR low-risk genotypes, MI multiple HPV infections, MSM men who have sex
le infection
ile and anal area total samples and did not take scrotum location into
Fig. 1 Number of high- and low-risk human papillomavirus (HPV) genotypes by infection type
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for each age group, respectively); however, none of
these differences were considered statistically signifi-
cant (p = 0.208 and p = 0.323, respectively; Table 2).
There was also no statistically significant difference be-
tween the age groups with regard to the type of infection
(single vs. multiple) or risk (high-risk genotypes, HPV 6
and/or HPV 11, low-risk genotypes) at the time of diag-
nosis (p > 0.05; Table 2).
PCA did not reveal any significant difference among
the distribution of the different HPV genotypes and
age. HPV 40, 67, 69, 70, 26, 68, and 82 were not
present in men <30 years, HPV 67 was only detected in
men >40 and high-risk genotypes 18 and 31 were found in
a total of 5 patients aged >40 while they were not detected
in men 31–40 years and only found in one patient aged
<30 years.
Number of sexual partners
The prevalence of multiple HPV infections and high-risk
genotypes increased proportionately with the number of







LR HR HPV 6,11 Total
<30 51 (37) 21 5 13 26
30–40 44 (31.9) 13 3 8 16
>40 43 (31.1) 11 3 6 15
Total 138 45 11 27 57
Statistics p-value 0.82 1.00 0.80 0.21
Chi-square 0.387 0.008 0.443 3.144
HPV 6,11 infections where HPV6 and/or HPV11 were detected, HR high-risk genotyp
genotypes(Fig. 2). Single infections and low-risk HPV genotypes
were more frequently found in monogamous men while
multiple HPV infections and high-risk genotypes were
more common in individuals with more than one sexual
partner (p < 0.01). For example, only 10/33 (30.3 %) with
<2 lifetime sexual partners had a high-risk HPV genotype
(similar in MSM [29 %] and heterosexuals [31 %]), while
this was 43/83 (52 %) in those with 2–5 partners (67 % in
MSM and 45 % in heterosexuals; Table 3).
Analysing HPV genotypes individually, PCA revealed
that genotypes 6, 16, and 84 were present in a higher
proportion among those who had a higher number of
lifetime sexual partners. These 3 genotypes were
found in 51.5 %, 57.8 %, 64.3 %, and 75 % samples
from men that had had <2, 2–5, 6–10, and >10 life-
time sexual partners, respectively. Statistical analysis
did not reveal any statistical difference between HPV
6 and 84 prevalence and number of lifetime sexual
partners (p > 0.05) but for HPV 16 differences were
statistically significant. HPV 16 presence was more
prevalent as the number of lifetime sexual partners
increased (p < 0.05; Table 3).ge, infection type and oncogenic risk
Multiple infection
LR HR HPV 6,11 OLR OHR Total
19 18 11 7 3 25
24 19 14 6 3 28
25 23 11 4 2 28
68 60 36 17 8 81
0.40 0.46 0.72 0.472 0.83 0.21
1.829 1.569 0.654 1503 0.384 3144
es, LR low-risk genotypes, OHR only high-risk genotypes, OLR only low-risk
Fig. 2 Distribution of oncogenic risk and HPV infection type by number of sexual partners. MILR: multiple HPV infection that presented only
low-risk genotypes; MIHR: multiple HPV infection that presented at least one high-risk genotype; SILR: single HPV infection that presented low-risk
genotypes; SIHR: single HPV infection that presented high-risk genotypes
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Fifty four men (39.1 %) confirmed that they had sexual
relationships with other men while 84 (60.9 %) con-
firmed themselves as heterosexual. In general, men in
the MSM group had a higher number of sexual partners
than heterosexuals and as such the risk of becoming in-
fected with HPV 16 or another high-risk HPV genotype
as well as having a multiple infection was higher
(Table 3). Multiple infections with more than five HPV
genotypes were more frequently found in the MSM
group than in heterosexual men (11 samples vs. 2
samples).
Eight HPV genotypes (HPV 33, 40, 42, 52, 55, 58, 82,
and CP6108) were more frequent in heterosexuals than
men in the MSM group (Fig. 3), with HPV 40 only de-
tected in heterosexuals. The remaining HPV genotypes
were more prevalent in men in the MSM group, with
HPV 67 and 69 only present in this group.
PCA analysis revealed a high frequency of HPV 16 and
HPV 84 in MSM compared with heterosexuals but only
the presence of HPV 16 was significantly different between
these groups (p < 0.01). Men in the MSM group tended to
have a higher risk of being infected with HPV 16 (Table 3).Table 3 Prevalence of at least one high-risk human papillomavirus (
Number of lifetime sexual partners
<2 2–5 6–10 >10
Sexual behaviour
MSM 2/7 (29) 18/27 (67) 10/12 (83) 7/8 (88
Heterosexual 8/26 (31) 25/56 (45) 1/2 (50) 0
Statistics
Column for number of lifetime sexual partners shows all high-risk genotypes found
oncogenic HPV 16 and low-risk HPV 6 and HPV 84 presence in total specimens
MSM men that had sex with menDiscussion
HPV genotype distribution studies in men are limited,
especially in Spain, a country where HPV infection
prevalence is reported to be low [17, 18]. There are few
reports about HPV prevalence and most of them refer to
women. This is the first study carried out in the Basque
Country and it indicates that 75 % of men who attended
our clinic with genital area clinical manifestations poten-
tially caused by HPV infection, were confirmed to have
an HPV infection.
Benign lesions are often caused by low-risk HPV geno-
types with genotypes 6 and 11 causing 90 % of genital warts
[1, 8]. However, in the present study, low-risk geno-
types HPV 6 or HPV 11 were only found in 63/138
(45.6 %) of the samples and 24 of these samples were
also positive for at least one high-risk HPV genotype.
In this study, the prevalence of multiple HPV
infections and high-risk HPV genotypes were high.
Multiple HPV infections were more frequent than
single infections (58.7 % vs. 41.3 %) and 51.4 % of
total samples were infected with at least one high-risk
HPV genotype. Furthermore, high-risk genotypes were
more often detected in multiple infections, whileHPV) genotype by sexual behaviour
HPV specific genotypes
HPV 6 HPV 16 HPV 84
%) 21/54 (39) 18/54 (33) 10/54 (19)
30/84 (36) 12/84 (14) 8/84 (10)
Chi square = 0.14 Chi square = 7.01 Chi square = 2.345
p = 0.706 p = 0.008 p = 0.126
in different groups whereas HPV specific genotypes column includes only















































Fig. 3 HPV risk genotypes presence and sexual behaviour. Genotypes prevalence proportion. MSM Men who have sex with other men
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genotypes (p < 0.01).
Data on the prevalence of HPV infections in men with
genital warts is unclear; however, a high prevalence of
some high-risk HPV genotypes, such as HPV 16, in
asymptomatic men has been reported [19, 20]. In this
study, the HPV 16 genotype was the most commonly
oncogenic type detected.
It is important to note that these data do not imply
that most lesions are caused by high-risk genotypes. It is
very likely that low-risk genotypes (HPV 6 and/or 11)
are the genotypes responsible for causing the lesion and
that high-risk genotypes are present due to patients’ sex-
ual activity. In this study, we showed that presence of
HPV 16 was significantly higher in men who had had
more lifetime sexual partners.
In our study, HPV DNA was not detected in 46 sam-
ples. Negativity with the Linear Array HPV Genotyping
Test kit used may be due to specimen inadequacy,genotyping method insensitivity, or the inability of the
kit to detect the existence of HPV genotypes other than
the 37 genotypes that the kit is capable of identifying.
Johansson et al. used metagenomic sequencing methods
for testing apparently negative HPV condyloma acumi-
nata and found out that most of them were HPV posi-
tive [21]. This may also explain why 19 samples in this
study were positive for only high-risk HPV genotypes.
Sequencing methods would be required in order to con-
firm whether low-risk genotypes were negative in these
samples. Even though HPV is considered to be a signifi-
cant cause of cancer, there are other important risk fac-
tors associated, such as sexual behaviour and number of
lifetime sexual partners [22]. We attempted to evaluate
these risk factors; however, more data are necessary
(especially regarding changes in HPV over time) in
order to establish an association between HPV geno-
type and both viral persistence and progression of
HPV-related clinical manifestations.
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creases with the number of sexual partners [11, 23–27].
Giuliano and Kjaer et al. found a strong association
between the acquisition of a new HPV infection and the
number of sexual partners [23, 26]. In this study, in
accordance with the literature, the presence of multiple
infections, HPV 16 and overall high-risk HPV genotypes
were significantly higher in men with more than one life-
time sexual partner (p < 0.05). Men in the MSM group
had had more lifetime sexual partners and as such the risk
of having HPV 16 or at least one oncogenic HPV genotype
as well as a multiple HPV infection were also higher in
the MSM group.
According to the results of this study, there was no as-
sociation between the prevalence of any HPV genotype
and age, confirming previous findings [24, 25, 27, 28];
however a trend towards a higher proportion of high-
risk genotypes with increased age was seen; a larger data
set/sample size may help to confirm or discard the sig-
nificance of this trend between genotype and age.
These results confirm that HPV infection and reinfec-
tion are strongly associated with sexual activity, and sup-
port earlier data suggesting that this, and not differences
in natural immunity, is the most important factor re-
garding infection/reinfection risk [29].
There is a wide variation in clearance rates of the vari-
ous oncogenic HPV genotypes; however, it is well known
that the clearance rates for high-risk HPV types are lower
than for non-oncogenic types, but clearance of all geno-
types increases with age [25] – which may be a factor of
decreased sexual activity with age. The trend towards a
greater prevalence of oncogenic HPV in older men may
be due to the higher persistence of oncogenic HPV geno-
types compared with low-risk genotypes.
There are no available approved routine screening tests
for genital warts, anogenital cancer, or HPV status in gen-
eral [4, 6, 10]. In order to accurately estimate HPV geno-
type prevalence and distribution in men, the detection of
the virus in its three manifestations (clinical, subclinical,
and latent forms) is required. Estimation of subclinical
and latent forms has been carried out by numerous stud-
ies assessing HPV prevalence, incidence, and clearance
among asymptomatic men and reported HPV prevalence
rates vary widely [10, 20, 25]. This may be due to differ-
ences in detection and sampling methods, the study popu-
lation, and geographical locations [5, 10, 30].
One method to estimate HPV prevalence involves col-
lecting specimens from patients who attend hospital
clinics with suspected HPV-related conditions, as we have
done in this study. However, as infections usually occur
without symptoms and most individuals only go to the
hospital when a clinical manifestation, such as a genital
wart or cancer, is apparent, this method is likely to be
inaccurate to estimate HPV general prevalence in men.More knowledge on the HPV distribution in men is
essential for three main reasons: i) the information
collected is valuable from the point of view of HPV as-
sociation with anogenital cancers and genital warts
(with follow up studies), ii) the fact that men act as
transmitters of HPV infection to both women and men
and, iii) to establish a database about the diversity and
pathogenicity of different HPV genotypes, which may
help to design and optimize treatment and vaccination
protocols in order to reduce the disease in men, and
consequently in women.
Conclusion
Although it is accepted that HPV 6 and 11 genotypes
are main causes of benign condylomas, our findings
show a high incidence of multiple infections and high
oncogenic risk genotypes in men with benign HPV
manifestations.
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